PDCD1 and cancer: Retrospective analysis of the efficacy of anti-CTLA-4, anti-PD-1, and/or anti-PD-L1 in more than 1600 patients, with 10 different types of cancer, revealed that immune checkpoint inhibitors were more efficient as the tumor mutational burden (TMB) or foreignness of the cancer was increased [326].